NEW YORK (GenomeWeb) – Quanterix announced it has licensed two assays from Banyan Biomarkers to bolster its research-use test menu for traumatic brain injury (TBI).

Under the terms of the agreement, Lexington, Massachusetts-based Quanterix will develop the Banyan UCH-L1 and GFAP assays for its Simoa single-molecule array technology. It will also incorporate the biomarkers into multiplex assays for research use in neurology.

Financial and other terms of the agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A genome-wide association study highlights a potential role for hair follicles in acne risk, according to New Scientist.

Newsday reports that breast cancer genetic testing guidelines for are out of date and may miss individuals.

In Cell this week: gene editing-based strategy to screen for immune system regulators, ancient plague patterns, and more.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.